InspireMD Inc Dossier - Source-backed chat

InspireMD Inc

NSPRNASDAQ

SectorHealth Care

IndustryHealth Care Equipment

Beta (adjusted)0.85

Intrinsic Value

No headline value published yetWe haven't published a headline intrinsic value for this company yet. Our data-reliability standards weren't met. Method estimates are shown for reference.

Market Price $0.62Price as of 1 Oct 2026

Data confidence Sign in to view data confidence

Market Cap $29M

Enterprise Value $17M

Shares Outstanding 46.8M diluted

Next Earnings Date10 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

InspireMD is a high-growth medical device company transitioning into a major player in the carotid artery disease and stroke prevention market. Despite a temporary setback from a voluntary U.S. recall of its CGuard Prime 135 cm delivery system, the underlying CGuard stent implant continues to demonstrate best-in-class clinical outcomes. The company's near-term catalysts—including expected FDA approval of its original CGuard delivery system in Q3 2026 and the CGuard Prime 80 cm for TCAR procedures in H2 2026—provide a clear path to commercial recovery and significant market expansion.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets3 analysts · as of 18 Aug 2026

Low · most bearish analyst$3.00

Mean target$3.67

High · most bullish analyst$4.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$1.2020%

Regulatory approvals for the original CGuard delivery system and the TCAR-indicated 80 cm device face unexpected FDA delays into 2027. The redesign of the 135 cm delivery system takes longer than anticipated, extending the commercial pause in the U.S. and increasing cash burn. Elevated operating expenses to support the U.S. commercial infrastructure without corresponding revenue growth force dilutive capital raises under the newly authorized share expansion.

Base CaseCentral scenario

$3.0050%

FDA approval for the original CGuard delivery system is secured in Q3 2026, allowing U.S. commercial sales to resume. The CGuard Prime 80 cm for TCAR is approved in late 2026, doubling the addressable U.S. market. The redesigned CGuard Prime 135 cm delivery system is approved and launched in H1 2027. International sales maintain steady double-digit growth, and the company leverages its strong cash position ($41.6M as of Q1 2026) to fund operations through commercial inflection.

Bull CaseUpside scenario

$5.0030%

Rapid FDA approvals of the original CGuard delivery system in Q3 2026 and the CGuard Prime 80 cm for TCAR in H2 2026 trigger immediate commercial acceleration. The company successfully resolves the 135 cm delivery system issues ahead of schedule, returning to full U.S. commercialization by early 2027. Strong international demand continues to scale, and the SwitchGuard NPS clinical trial (CGUARDIANS III) progresses smoothly toward a 2027 launch, capturing a dominant share of the $1B+ carotid stenting market.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Best-in-class clinical data from the CGUARDIANS trials demonstrating 100% acute success and zero major adverse events (strokes, deaths) at 30 days.
Near-term regulatory catalysts with two expected FDA approvals in the second half of 2026 (original CGuard delivery system and CGuard Prime 80 cm for TCAR).
TCAR market entry represents a massive expansion opportunity, potentially doubling the company's addressable U.S. market.
Strong balance sheet with $41.6 million in cash, cash equivalents, and marketable securities as of March 31, 2026, providing runway to execute the commercial strategy.

Key Investment Risks

Regulatory risk associated with potential delays in FDA approvals for the original delivery system and the TCAR-indicated device.
Execution risk in successfully redesigning and relaunching the CGuard Prime 135 cm delivery system following the voluntary recall.
Commercial adoption risk as the company competes against established medical device giants with significantly greater resources.
High cash burn rate from elevated operating expenses ($14.7M in Q1 2026) to support commercial infrastructure during the temporary U.S. sales pause.

Thesis Invalidation Triggers

FDA rejection or material delay of the original CGuard delivery system approval beyond 2026.
Failure of the CGUARDIANS III clinical trial to meet safety or efficacy endpoints for the SwitchGuard NPS.
Significant cash depletion requiring highly dilutive equity financing before achieving commercial inflection.
Inability to resolve the technical issues of the CGuard Prime delivery system, leading to a permanent loss of the U.S. CAS market share.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.